Not a Blockbuster -- Yet

As expected after a unanimous advisory panel vote last month, the FDA approved Merck's (NYSE: MRK  ) HIV drug ISENTRESS on Friday. While that's good news for HIV patients, Merck's investors will have to wait a while before they can truly reap the financial benefits of this potential blockbuster drug.

The drug was approved under an accelerated FDA approval process that allows drugs that treat diseases with unmet needs to be approved with less safety and efficacy data than is normally required. But that speed comes with a price -- ISENTRESS is only approved for use in patients who have already failed other safety-proven treatments.

The drug is the first in a class of integrase inhibitors, which block the viral DNA from integrating with the patient's DNA. Because it blocks a new mechanism of viral replication, the drug works well in patients who have developed resistance to current treatments, which block viral replication by attacking the protease or reverse transcriptase enzymes.

The drug should also work in patients who haven't gained resistance to other drugs, but Merck will need to complete ongoing phase 3 clinical trials in patients who aren't resistant before it can gain marketing approval for that segment of the patient population.

Merck should have the integrase inhibitor market to itself for a while. Its closest competitor is Gilead Sciences (Nasdaq: GILD  ) , which completed a phase 2 clinical trial earlier this year. Merck's big pharma brethren GlaxoSmithKline (NYSE: GSK  ) and Bristol-Myers Squibb (NYSE: BMY  ) also have integrase inhibitors, but they're further behind in the clinic.


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 538572, ~/Articles/ArticleHandler.aspx, 11/21/2014 6:03:54 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement